osteolabs GmbH establishes UK presence
Chris will assume the Managing Director/General Manager role for osteolabs UK Ltd. from May1, 2021 onwards. osteolabs UK plans to workwith clinical osteoporosis professionals across Great Britain in order to ensure easy and efficient access to the CE-marked OsteoTest for early detection of osteoporosis which was successfully introduced inGermanyand other European countries in 2020.
Osteoporosis represents a major disease burden in the UK with over 500,000 hospitalisations per annum as a result of osteoporotic fractures at a cost impactof over £4.4B.The innovative, CE-marked OsteoTest is protected by patent and has been clinically validated in several studies. It can be used both to detect osteoporosis and to monitor therapy. Up to now, patients have had to be exposed to X-rays for adiagnosis -in most cases when osteoporosis has already occurred.
“I am thrilled to establish and to lead this joint venture together with osteolabs, a leading player for early detection of osteoporosis. This is a devastating disease affecting millionsof patients per year” said ChrisBrain, incoming Managing Director of osteolabs UK Ltd.
“We are very happy to have partnered with Chris who is a very experienced Medtech commercial leader with many years of business experience. Together, we see a tremendous opportunity to bring our well established OsteoTest to the UK market” added Dr. Stefan Kloth, CEO of osteolabs GmbH.
Lastly, Dr. Bernd Buchholz, Minister of Economic Affairs of the Federal State of Schleswig-Holstein commented :"osteolabs is a perfect example of an innovative playerin the state who is courageously paving its way and expanding the business despite the ongoing pandemic. I am very pleased to see that know-how from Schleswig-Holstein is now being applied more and more internationally through partnerships and now the formation of a joint venture with a leading UK partner.”
Biotech & Pharma
Sysmex Europe SE is listed in the top 100 best workplaces
Biotech & Pharma